Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil

Autores
Bardach, Ariel Esteban; Ballivian Cuellar, Jamile Rusbania; Bagattini, Ângela Maria; Machado da Rosa, Michelle Quarti; Moura de Oliveira, Max; Gomez, Jorge A.; Casarini, Agustín
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339-1424) and median length of stay (4-5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 -16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.
Fil: Bardach, Ariel Esteban. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Ballivian Cuellar, Jamile Rusbania. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Bagattini, Ângela Maria. Universidade Federal de Goiás; Brasil
Fil: Machado da Rosa, Michelle Quarti. Universidade Federal de Goiás; Brasil
Fil: Moura de Oliveira, Max. Universidade Federal de Goiás; Brasil
Fil: Gomez, Jorge A.. No especifíca;
Fil: Casarini, Agustín. Instituto de Efectividad Clínica y Sanitaria; Argentina
Materia
Brazil
Herpes zoster
economic burden
older adults
post herpetic neuralgia
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/291243
Acceder
id CONICETDig_28c122f1be7ce9eece7dfc0636d04553
oai_identifier_str oai:ri.conicet.gov.ar:11336/291243
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in BrazilBardach, Ariel EstebanBallivian Cuellar, Jamile RusbaniaBagattini, Ângela MariaMachado da Rosa, Michelle QuartiMoura de Oliveira, MaxGomez, Jorge A.Casarini, AgustínBrazilHerpes zostereconomic burdenolder adultspost herpetic neuralgiahttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3In Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339-1424) and median length of stay (4-5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 -16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.Fil: Bardach, Ariel Esteban. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Ballivian Cuellar, Jamile Rusbania. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Bagattini, Ângela Maria. Universidade Federal de Goiás; BrasilFil: Machado da Rosa, Michelle Quarti. Universidade Federal de Goiás; BrasilFil: Moura de Oliveira, Max. Universidade Federal de Goiás; BrasilFil: Gomez, Jorge A.. No especifíca;Fil: Casarini, Agustín. Instituto de Efectividad Clínica y Sanitaria; ArgentinaTaylor & Francis2025-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/291243Bardach, Ariel Esteban; Ballivian Cuellar, Jamile Rusbania; Bagattini, Ângela Maria; Machado da Rosa, Michelle Quarti; Moura de Oliveira, Max; et al.; Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil; Taylor & Francis; Human Vaccines & Immunotherapeutics; 21; 1; 7-2025; 1-102164-55152164-554XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2520066info:eu-repo/semantics/altIdentifier/doi/10.1080/21645515.2025.2520066info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T15:36:53Zoai:ri.conicet.gov.ar:11336/291243instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 15:36:53.574CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
title Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
spellingShingle Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
Bardach, Ariel Esteban
Brazil
Herpes zoster
economic burden
older adults
post herpetic neuralgia
title_short Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
title_full Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
title_fullStr Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
title_full_unstemmed Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
title_sort Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil
dc.creator.none.fl_str_mv Bardach, Ariel Esteban
Ballivian Cuellar, Jamile Rusbania
Bagattini, Ângela Maria
Machado da Rosa, Michelle Quarti
Moura de Oliveira, Max
Gomez, Jorge A.
Casarini, Agustín
author Bardach, Ariel Esteban
author_facet Bardach, Ariel Esteban
Ballivian Cuellar, Jamile Rusbania
Bagattini, Ângela Maria
Machado da Rosa, Michelle Quarti
Moura de Oliveira, Max
Gomez, Jorge A.
Casarini, Agustín
author_role author
author2 Ballivian Cuellar, Jamile Rusbania
Bagattini, Ângela Maria
Machado da Rosa, Michelle Quarti
Moura de Oliveira, Max
Gomez, Jorge A.
Casarini, Agustín
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Brazil
Herpes zoster
economic burden
older adults
post herpetic neuralgia
topic Brazil
Herpes zoster
economic burden
older adults
post herpetic neuralgia
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339-1424) and median length of stay (4-5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 -16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.
Fil: Bardach, Ariel Esteban. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Ballivian Cuellar, Jamile Rusbania. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Bagattini, Ângela Maria. Universidade Federal de Goiás; Brasil
Fil: Machado da Rosa, Michelle Quarti. Universidade Federal de Goiás; Brasil
Fil: Moura de Oliveira, Max. Universidade Federal de Goiás; Brasil
Fil: Gomez, Jorge A.. No especifíca;
Fil: Casarini, Agustín. Instituto de Efectividad Clínica y Sanitaria; Argentina
description In Brazil, as the older population has grown at a very rapid pace (by 57.4% over 2010), the number of herpes zoster (HZ) infections is expected to increase. As the Brazilian healthcare system constitutes a complex combination of public-private financing, estimating the true impact of HZ is challenging. The objective was to ascertain the disease burden of HZ and estimate its attributable cost in older adults aged ≥50 y who are users of public and private health services. Disease burden was estimated based on the ZOster ecoNomic Analysis model using Brazil-specific inputs, and any information gap was addressed by the Delphi Panel. The incidence estimates were multiplied by the cost per intervention to calculate the economic burden of the disease. In the absence of HZ vaccination, older adults ≥50 y are projected to experience 359,797 and 23,917 cases of HZ and post-herpetic neuralgia (PHN), with frequent and severe outcomes in the advanced age groups. The estimated mean cost of treatment per patient for HZ and PHN was ~7X and 16X more in the ANS population compared with the SUS. The number of hospitalizations (1339-1424) and median length of stay (4-5 d) were comparable between ANS and SUS. Hospitalization increased the treatment cost >10X (ANS: R$12459.67 -16,343.07; SUS: R$357.93 to 525.08). HZ imposes a substantial economic burden on the healthcare system due to high direct medical (R$357.36 million) and indirect costs (R$440.82 million). These results hold valuable insights for healthcare providers, insurers, and policymakers offering a comprehensive overview of the economic impact of HZ while implementing strategies for prevention of disease.
publishDate 2025
dc.date.none.fl_str_mv 2025-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/291243
Bardach, Ariel Esteban; Ballivian Cuellar, Jamile Rusbania; Bagattini, Ângela Maria; Machado da Rosa, Michelle Quarti; Moura de Oliveira, Max; et al.; Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil; Taylor & Francis; Human Vaccines & Immunotherapeutics; 21; 1; 7-2025; 1-10
2164-5515
2164-554X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/291243
identifier_str_mv Bardach, Ariel Esteban; Ballivian Cuellar, Jamile Rusbania; Bagattini, Ângela Maria; Machado da Rosa, Michelle Quarti; Moura de Oliveira, Max; et al.; Modeling the herpes zoster disease burden and its potential health impact on older adults >50 years of age in Brazil; Taylor & Francis; Human Vaccines & Immunotherapeutics; 21; 1; 7-2025; 1-10
2164-5515
2164-554X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2520066
info:eu-repo/semantics/altIdentifier/doi/10.1080/21645515.2025.2520066
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874775556846780416
score 13.24418

Publicaciones similares